Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer

Fig. 8

Validation of gene expression in three TNBC cell lines. A. Effect of JQ1 and GSK2801 on TAGLN and KISS1 genes in the MDA-MB-231 cells showing the downregulation in the expression both in the single and combined treatments. B. Effect of JQ1 and GSK2801 on MUC19 and KCNB1 genes in SUM-159 cells showing the downregulation in the expression. MUC19 was found to be upregulated with a higher concentration of JQ1 (250 nM). C. Effect of JQ1 and GSK2801 on MUC19, KCNB1 and KISS1 genes in HCC-1806 cells lines. MUC19 was upregulated by GSK2801 (10 µM). The increase in the JQ1 concentration in the combined treatments increased the expression of KCNB1. KISS1 was observed to be downregulated in all the single and combined treatments. Values are given as mean of three independent experiments ± SD. Statistical significance were defined at *p < 0.05 compared to DMSO control. DMSO: control, J: JQ1, G: GSK2801. JQ1 doses are in nM and GSK2801 in µM

Back to article page